Sebacoyl Dinalbuphine Ester
Small molecule
Sebacoyl Dinalbuphine Ester is one of 71 small molecule programs targeting Hemorrhoid. It is currently in development.
2
Indications
2
Total Trials
1
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
230 competitors in Cesarean Section
#DrugCompanyPhaseTrials
1Marcaine
IInnocoll
Preclinical
Naropin
FFresenius Kabi Oncology Ltd.
Preclinical
Proamatine
TakedaPreclinical
Dynastat
PfizerPreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Catapres
Boehringer IngelheimPreclinical
Ancef
BBaxter Healthcare Corporation
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Neurontin
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hemorrhoid1 trial
Cesarean Section1 trial
Dinalbuphine Ester (Naldebain) for Pain Management After Cesarean Section
Recruiting·—·Phase 2/3·NCT06344169·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sebacoyl Dinalbuphine Ester. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- LLumosa Therapeutics Co., Ltd.